Phase II Single-Arm Trial of Cladribine and Low-Dose Cytarabine Alternating with Decitabine as Frontline Therapy for Older Patients with Acute Myeloid Leukemia

BACKGROUND: Frontline therapy for older and/or unfit patients with acute myeloid leukemia (AML) remains unsatisfactory. We studied a new lower-intensity regimen of cladribine combined with low-dose cytarabine (LDAC) alternating with decitabine (DAC) aimed to improve outcomes in this population Based...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Lancet Haematol
Prif Awduron: Kadia, Tapan M., Cortes, Jorge, Ravandi, Farhad, Jabbour, Elias, Konopleva, Marina, Benton, Christopher B., Burger, Jan, Borthakur, Gautam, DiNardo, Courtney D., Pemmaraju, Naveen, Daver, Naval, Ferrajoli, Alessandra, Wang, Xuemei, Patel, Keyur, Jorgensen, Jeffrey L., Wang, Sa, O’Brien, Susan, Pierce, Sherry, Tuttle, Carla, Estrov, Zeev, Verstovsek, Srdan, Garcia-Manero, Guillermo, Kantarjian, Hagop
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2018
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6775639/
https://ncbi.nlm.nih.gov/pubmed/30115541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3026(18)30132-7
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg